Immunotherapeutic Agents for SLE

The authors of this book have addressed a variety of innovative relevant management issues for the treatment of systemic lupus erythematosus (SLE), which are already available or under active validation.

Source: Future Medicine, Ltd.
Author(s): Schoenfeld, Yehuda; Meroni, Pier Luigi; Cervera, Ricard
ISBN-10: 1780840527

Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease whose pathogenesis is multifactorial relying on genetic and environmental factors and on abnormalities of both the innate and the adaptive immune system. The approach to SLE has rapidly evolved over the last few years. Our diagnostic power has dramatically improved as well as our skill in treating the major complications of the disease. This is particularly true for the kidney involvement. On the other hand, physicians taking care of lupus are aware of the potential cardiovascular comorbidity and are ready to start aggressive primary prophylaxis. The availability of new (and innovative) drugs raises the concrete possibility to hypothesize different therapeutic strategies tailored to individuals depending on the clinical subtypes.